Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermediate-dose enoxaparin in hospitalized patients with moderate-severe COVID-19 (INHIXACOVID19)
2020-001308-40Phase 2Completed
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enoxaparin in coronavirus disease 2019 (COVID-19) and viral pneumonia, sponsored by Alma Mater Studiorum – Università di Bologna. Primary endpoints: All-cause in-hospital mortality, All-cause 30-day mortality and 1 more. Started Jun 2020; status: completed.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on 2020-001308-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001308-40.